[PRESS RELEASE] – NEW YORK, Sept. 23, 2025 – Mamedica, the U.K.'s leading and most-trusted provider of cannabis-based prescription medicines, announced a £4.5 million funding round led by Casa Verde, the U.S.-based cannabis-focused venture capital firm.
Casa Verde has backed major cannabis companies, including Dutchie, Metrc and Leaflink, in the United States, and holds European positions in Cansativa and Sanity Group. The new capital will be used to scale Mamedica's operations by optimizing its in-house supply chain for efficiency and continuity of care, expanding access through a wider clinical network, advancing its proprietary digital health care platform with enhanced automation and compliance capabilities, and driving education around the integration of medical cannabis into mainstream health care.
Launched in 2022 by founder and CEO Jon Robson, Mamedica provides specialist treatment for chronic and neurological conditions, including pain, anxiety, ADHD and depression. Its digital model enables remote consultations with specialist clinicians, with medication delivered nationwide by secure next-day courier.
Since its inception, Mamedica has treated over 10,000 patients, with approximately 7,500 actively under care, and around 10% month-on-month growth in initial consultations. The company recorded 1,250% patient growth in 2023 and 154% in 2024 and expects to double patient numbers annually as the U.K. medical cannabis industry approaches £1 billion in annual sales by the end of 2028.
"We're excited to partner with Mamedica as the U.K. cannabis market enters a period of rapid growth," said Karan Wadhera, managing partner at Casa Verde. "Mamedica's digital-first, patient-centric model sets the standard for care in the U.K. and offers a blueprint for broader European expansion."
"This funding marks a pivotal milestone in Mamedica's mission to transform patient care in the U.K.," Robson said. "The backing of Casa Verde and our private investors validates our approach and enables us to accelerate access to high-quality, regulated treatment."
